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Abstract
This study evaluated combination drug partners for CP-4055, the C18:1
D9,trans unsaturated fatty acid ester of cytarabine in
HL-60 and U937 cells. Growth inhibition was assessed by ATP assay and drug interaction by the combination index and
three dimensional methods. Synergy was observed in HL-60 cells for simultaneous combinations of CP-4055 with
gemcitabine, irinotecan and topotecan, while combinations with cloretazine (VNP40101M) and idarubicin were additive. In
U937 cells, synergy was observed with gemcitabine and additivity for the other drugs. In HL-60, the IC50 concentration of
CP-4055 could be reduced 10-fold and that of gemcitabine 3-fold in combination versus the agents alone, an interaction that
was independent of drug sequence, ratio and exposure time. In contrast, interactions of CP-4055 with the topoisomerase
inhibitors became antagonistic when the drugs were administered 24 h prior to CP-4055 and at certain drug ratios,
particularly in U937 cells. In summary, CP-4055 produced additive to synergistic anti proliferative activity when combined
simultaneously with drugs from four mechanistic classes in cell culture models of human leukemia and lymphoma. The
impact of drug sequence and ratio on the interactions argues for incorporation of these parameters into the design of
combination chemotherapy regimens.
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Introduction
Cytarabine (ara-C) is the most active single agent in
acute myelogenous leukemia (AML) and is also
important for treatment of acute lymphocytic leuke-
mia, chronic myelogenous leukemia and non-
Hodgkin lymphoma. The active metabolite of
cytarabine is ara-CTP and monophosphorylation by
deoxycytidine kinase (dCK) is the rate-limiting step
in its synthesis. Ara-CTP causes both reversible and
irreversible inhibition of DNA synthesis via inhibi-
tion of DNA polymerase and by incorporation into
DNA with induction of apoptosis, respectively [1].
Accumulation of ara-CTP in leukemic blasts corre-
lates with clinical response; however, this process is
limited by rapid deamination to uracil arabinoside by
cytidine deaminase in blood, liver, kidney and
intestine. Cellular resistance to cytarabine can also
occur via multiple mechanisms, including altered
nucleoside transport and reduced intracellular dCK
activity [2,3]. Combination chemotherapy is often
employed to overcome such limitations and syner-
gistic interactions of cytarabine with purine nucleo-
side analogs have been exploited for some time [4].
Recently, synergy has also been reported for combi-
nations of cytarabine with gemcitabine, another
pyrimidine nucleoside analog [5–7].
To enhance cellular uptake, decrease inactivation
and prolong exposure to ara-CTP, the elaidic
acid ester of cytarabine, CP-4055 was developed.
Correspondence: David J. Adams, DUMC 2638, Research Drive, Durham, NC 27710, USA. Tel: þ919-684-4383. Fax: þ919-668-3925.
E-mail: adams041@mc.duke.edu
Leukemia & Lymphoma, April 2008; 49(4): 786–797
ISSN 1042-8194 print/ISSN 1029-2403 online  2008 Informa UK Ltd.
DOI: 10.1080/10428190801935752Accordingly, CP-4055 enters cells by a nucleoside
transporter-independent mechanism and exhibits
longer intracellular retention with accompanying
longer inhibition of DNA synthesis [8–10]. Unlike
ara-C, CP-4055 also causes transient inhibition of
RNA synthesis, is active in cytarabine-resistant
tumours and has Phase I activity in solid tumours,
including melanoma, non-small cell lung cancer and
lung cancer refractory to gemcitabine [11,12].
Clinically, CP-4055 is well tolerated in patients
with hematologic malignancies at bolus doses of
875 mg/m
2/d and by continuous infusion of 675 mg/
m
2/d given daily for 5 days every 3 weeks [13]. The
present study was undertaken to identify combina-
tion drug partners for CP-4055 in acute myeloid
leukemia and lymphoma. Two complementary ap-
proaches were utilised to evaluate drug interaction:
the combination index and combination effect
methods. In addition, the study sought to deﬁne
optimal treatment parameters for synergistic or
additive drug combinations, including effects of
drug sequencing, drug ratio and the relative impact
of drug concentration and time of exposure on tumor
growth inhibition. The results underscore the im-
portance of these parameters in drug interaction,
since the type of interaction was highly sequence and
ratio-dependent for certain combinations. Overall,
the synergistic anti proliferative activity of CP-4055
combined with gemcitabine proved to be the most
robust, being largely independent of sequence, ratio




CP-4055 was obtained from Clavis ASA (Oslo,
Norway) and stored at room temperature. Cloreta-
zine
TM (VNP40101M; Vion Pharmaceuticals, Inc.
New Haven, CT), and idarubicin (Sigma-Aldrich,
St. Louis, MO) were stored at 2–88C. Concen-
trated stock solutions of these agents were prepared
in cell culture grade dimethylsulfoxide (Sigma-
Aldrich) and stored at 7208C. Clinical formula-
tions of cytarabine, gemcitabine, topotecan and
irinotecan were obtained from Bedford Laboratories
(Bedford, MA), Eli Lilly (Indianapolis, IN), Glaxo
SmithKline (Research Triangle Park, NC), and
Pﬁzer (New London, CT), respectively and stored
at room temperature.
Cell lines and culture conditions
Cell lines were obtained from the American Type
Culture Collection, Manassas, VA through the Duke
Cell Culture Facility and were mycoplasma-free.
HL-60 is a promyelocytic cell line derived from
peripheral blood leukocytes of a 36-year-old Cauca-
sian female with acute promyelocytic leukemia [14].
The cells are pseudo-diploid, p53 negative and
express the myc oncogene, but do not express the
PML-RAR fusion protein commonly found in APL.
The cells also have a deletion of the 5q31 region, a
frequent clonal chromosomal abnormality found in
human myelodysplastic syndrome and acute myeloid
leukemia that is thought to contribute to the
pathogenesis of these diseases by deleting one or
more tumor-suppressor genes [15]. HL-60 cells were
cultured in Iscove’s-modiﬁed Dulbecco’s medium
(ATCC, Manassas, VA), containing 4 mM L-
glutamine, 1.5 g/L sodium bicarbonate and 20%
fetal bovine serum (HyClone, Logan, UT). The
U937 cell line was derived from the pleural effusion
of a 37-year-old male Caucasian with histiocytic
lymphoma [16]. The cells were cultured in RPMI
1640 medium containing 4.5 g/L glucose, 10 mM
HEPES, 1 mM pyruvate and 10% fetal bovine
serum. Both cell lines were maintained in log phase
growth at a density of 4610
5–1610
6 cells/mL.
Growth inhibition and drug interaction assays
Growth inhibition and drug interaction in vitro
assays have been described previously [17]. Brieﬂy,
cells were seeded at 2610
4/well/200 mL in 96 well
conical-bottom microplates. Following drug addition
one (HL-60) or 24 h (U937) later, cells were
incubated for 48 h (*2 cell doublings) and then
40 mL/well were assayed for ATP as a biomarker for
viable surviving cells utilizing the ATPLite
TM-M
luminescence Assay System (Perkin-Elmer, Wal-
tham, MA). The relation of cell number to lumines-
cence was linear from 2610
5 to 10 cells/well. Mean
fractional growth inhibition, deﬁned as (treated –
blank)/(untreated control – blank) was determined
from 3–4 replicate wells per dose. Individual dose-
response curves were then constructed and the IC50
computed from the best ﬁtting transition functions
(determined by F-statistic) using TableCurve 2D
curve-ﬁtting software (SPSS, Downers Grove, IL).
The IC50 is deﬁned as the drug concentration
producing 50% growth inhibition relative to un-
treated controls. Alternatively, composite dose re-
sponse curves were obtained from multiple
experiments and the median effective dose, Dm
(equivalent to the IC50), computed using CalcuSyn
software (Biosoft, Cambridge, UK; an updated
version of this software, termed CompuSyn is now
available from ComboSyn, Inc., Paramus, NJ).
Drug interaction was assessed by the combination
index method of Chou and Talalay (originally
CP-4055 combinations in leukemia/lymphoma 787described in [18]; recently reviewed in [19]). This
method is based on the median effect principle:
fa=fuðD=DmÞ
m ð1Þ
where D is administered dose, Dm is the dose that
yields 50% growth inhibition, fa is the cell fraction
affected by dose D, fu is the unaffected fraction, and
m is a coefﬁcient that deﬁnes the sigmoidicity of the
dose-effect curve.
This relationship and the law of mass action lead to
a generalised equation for the interaction of multiple
inhibitors
ðfaÞA;B=ðfuÞA;B ¼ð faÞA=ðfuÞB þð faÞB=ðfuÞB
þ aðfaÞAðfaÞB=ðfuÞAðfuÞB
ð2Þ
where (fa)A,( fu)B and (fa)A,B are the fractions affected
by drugs A and B alone and in combination,
respectively. From Eqs. (1) and (2), the equation
for the combination index (CI) can be derived as
CI ¼ð DÞA=ðDxÞA þð DÞB=ðDxÞB
þ aðDÞAðDÞB=ðDxÞAðDxÞB
ð3Þ
Where D is the dose that yields x% growth inhibition
and a¼0 for mutually exclusive drugs and a¼1 for
mutually non-exclusive drugs. Additivity is then
deﬁned as CI¼1; synergy as CI51; and antagonism
as CI41.
This study used the mutually exclusive assumption
(the drugs have similar sites of action) as incorpo-
rated in CalcuSyn software from at least three
replicate experiments.
Drug interaction was also assessed by the combi-
nation effect method of Kanzawa [20], which is
based on the three-dimensional model of Pritchard
and Shipman [21], and considers the drugs
mutually-non-exclusive.
This method deﬁnes theoretical additivity (TA)
based on Eq. (2) above as
TAðtÞ ¼ð faÞA þð faÞB  ð faÞAðfaÞB ð4Þ
The combination effect (CE) surface is then given by
fðSaÞA;BgCE ¼f ð SaÞA;Bgobs  f ð SaÞA;Bgcal ð5Þ
Here {(Sa)A,B}obs represents the observed effect, and







ðfaÞA þð faÞB  ð faÞAðfaÞB
  
ð6Þ
Additivity is deﬁned as CE¼0; synergy as CE50;
and antagonism as CE40.
This complementary approach was performed in
868 checkerboard format in six replicate plates.
The associated combination effect surface was
computed from mean values normalised by the
respective 95% conﬁdence limit. For sequencing
studies, drug exposures were separated by 24 h.
For studies addressing the impact of exposure
time on anti proliferative activity, replicate dose-
response plates were prepared that included CP-
4055 alone, gemcitabine alone, and CP-4055
combined with gemcitabine at a ratio of 1:0.0025
(HL-60) or 1:0.02 (U937). Following drug expo-
sure times of 1, 3, 9, 27 and 54 h, plates were
centrifuged for 5 min on a Sorvall RT-7 centrifuge
at 1000 rpm. Culture medium was removed and
replaced with fresh drug-free medium for a mini-
mum of 3 h. Cells were then assayed for ATP as
described above.
Results
Rationale for the choice of combination partners
The choice of potential combination partners for CP-
4055 included drugs with diverse structures (Figure
1) and mechanisms of action that have documented
clinical activity in leukemia/lymphoma. For example,
many chemotherapy regimens for AML contain an
anthracycline, which causes DNA damage via inhibi-
tion of topoisomerase II. Idarubicin represents a
second generation anthracycline with clinical activity
in AML that is less cardiotoxic and less susceptible to
multi-drug resistance. Similarly, topotecan and
irinotecan are topoisomerase I inhibitors clinically
approved for use in ovarian and small cell lung
cancer and in colorectal cancer, respectively. Irino-
tecan is active in combination with cytarabine in
refractory AML [22], while topotecan is active alone
and in combination in hematological malignancies
[23]. Gemcitabine is a nucleoside analog with activity
in both hematological and solid tumours. As a DNA
antimetabolite, gemcitabine causes masked chain
termination during DNA synthesis, which is difﬁcult
to repair. In addition, the dFdCDP metabolite of
gemcitabine potentiates the drug’s cytotoxicity.
dFdCDP inhibits ribonucleotide reductase, which
depletes deoxynucleotide pools that would otherwise
inhibit deoxycytidine kinase, the rate-limiting en-
zyme in formation of dFdCMP from gemcitabine as
well as ara-CMP from cytarabine. Gemcitabine can
also act by inhibiting topoisomerase I [24]. Clor-
etazine is a new antitumor agent that has shown
clinical activity in relapsed or refractory AML [25].
Cloretazine is a pro-drug whose unique activation
788 D. J. Adams et al.produces both carbamoylating and alkylating species
that lead to DNA damage [26].
CP-4055 exhibits signiﬁcant anti proliferative activity in
HL-60 and U937 cells
Using ATP as a metabolic endpoint, complete
sigmoid dose-response curves were obtained in
which the fraction of tumor cells affected ranged
from 100% to  10% (Figure 2). While the tradi-
tional IC50 was chosen as the endpoint for compar-
ison, an IC90 level of activity was also achieved by all
seven drugs. On a molar basis, gemcitabine was the
most potent agent in both cell lines, followed closely
by the topoisomerase inhibitors idarubicin and
topotecan (Table I). CP-4055 was three orders of
magnitude less potent than gemcitabine in HL-60
and two logs less potent in U937. This is not
surprising, since CP-4055, like cloretazine and
irinotecan, is a pro-drug that requires enzymatic
Figure 1. Structures of drugs under study.
CP-4055 combinations in leukemia/lymphoma 789conversion by esterases and kinases to its active form,
ara-CTP. Of interest, CP-4055 like cytarabine was
nearly 20-fold more potent in U937 compared with
HL-60. The other agents had comparable activity in
each cell line, with the exception of cloretazine,
which was 2-fold more active in U937 cells.
Simultaneous combinations with CP-4055 produce
additive to synergistic interactions
Median effect analysis of drugs combined simulta-
neously with CP-4055 at the approximate ratio of
their IC50’s revealed signiﬁcant synergy with
gemcitabine (CI¼0.4); moderate synergy with topo-
tecan and irinotecan (CI¼0.8), and additive inter-
actions with idarubicin and cloretazine in HL-60
cells (CI¼1.0; Table II). Addition of cloretazine or
idarubicin to the CP-4055-gemcitabine combination
did not signiﬁcantly alter the interaction. Similar
results for binary combinations were observed in
U937 cells, but the synergy between CP-4055 and
gemcitabine was only moderate (CI¼0.8; Table II).
Important for clinical translation, no antagonistic
interactions were observed with CP-4055 combina-
tions in this setting. In contrast, combinations of
idarubicin with cloretazine and with gemcitabine
elicited moderately antagonistic to antagonistic re-
sponses, respectively, in HL-60 cells (Table II).
Figures 3 and 4 extend the results in Table II to
include interaction at various levels of effect. Of note,
the CP-4055-gemcitabine combination becomes
more synergistic as anti proliferative activity increases
(C panels). The combination of cytarabineþ
gemcitabine showed synergy comparable to CP-
4055þgemcitabine in both cell lines (Figures 3
and 4, panel E).
To express the synergy of CP-4055 and gemcita-
bine in a more practical way, the dose reduction
index was computed across various levels of affect for
this combination in HL-60 cells (Table III). The
Figure 2. Composite dose-response curves in human leukemia cells. Data from replicate dose-response experiments for HL-60 (open circles)
and U937 (ﬁlled circles) leukemia cell lines were combined and the mean values plotted for the various drugs under study. Line: data ﬁt to
the Hill Equation (a form of the median-effect equation); bar: intra-assay standard error.




IC50 (nM) N IC50 (nM) N
CP-4055 13,387+1428 24 710+78 14
Cloretazine 136,150+11,146 7 59,996+13,852 7
Idarubicin 12.1+ 0.6 8 30+57
Gemcitabine 9.4+0.7 18 23+21 0
Irinotecan 4742+253 8 3823+518 7
Topotecan 20.2+1.0 7 34+27
Cytarabine 2989+322 5 167+29 4
790 D. J. Adams et al.results indicate that in combination, the doses of
both CP-4055 and gemcitabine can be reduced
signiﬁcantly and yet produce the same antitumor
activity as each agent alone. For example, at the IC50
(Fa¼0.5), the dose of CP-4055 can be reduced
nearly 10-fold and that of gemcitabine 3-fold when
used in combination. Providing the drug interaction
is tumour-selective, this result suggests that reduced
doses of CP-4055 combined with a relatively small
amount of gemcitabine could decrease toxicity with-
out loss of efﬁcacy.
Drug sequence impacts drug interaction
The impact of sequence of administration on drug
interaction in each cell line is shown in Figures 3
(HL-60) and 4 (U937). Results differed in the two
models. In HL-60 cells, interaction of CP-4055 with
the topoisomerase inhibitors exhibited a marked
sequence dependence with synergy occurring when
CP-4055 was given ﬁrst, additivity when given
together, and antagonism when CP-4055 was given
second (Figure 3, panels D, E). Synergy with
Table II. Combination index at the IC50 in human leukemia cells.
Molar ratio N CI
HL-60 Combination
CytarabineþGemcitabine 1:0.01 3 0.39+0.01
CP-4055þGemcitabine 1:0.0025 11 0.41+0.01
CP-4055þTopotecan 1:0.00125 6 0.78+0.01
CP-4055þIrinotecan 1:0.125 6 0.81+0.07
CP-4055þIdarubicin 1:0.0025 6 0.88+0.09
CP-4055þCloretazine 1:10 6 0.91+0.08
CloretazineþGemcitabine 1:0.00025 3 1.10+0.11
CloretazineþIdarubicin 1:0.00025 3 1.20+0.03











CP-4055þGemcitabine 1:0.02 8 0.82+0.04
CP-4055þCloretazine 1:40 6 0.94+0.10
CytarabineþGemcitabine 1:0.2 3 1.00+0.05
CP-4055þIrinotecan 1:2 4 1.11+0.02
CP-4055þTopotecan 1:0.02 4 1.11+0.06
CP-4055þIdarubicin 1:0.01 6 1.16+0.11
Figure 3. Combination index plots of Chou-Talalay and impact of drug sequence in HL-60 cells. Composite dose-response curves were
constructed for drugs alone and in combination as described in Methods. The respective fraction affected (Fa) was interpolated at 10 percent
Intervals and the values used to compute the combination index for simultaneous administration of CP-4055 (open circles), for CP-4055
given 24 h prior to (open triangles) or 24 h after (open squares) the second drug in the combination listed in each panel. For cytarabine, only
simultaneous combinations are shown combined with CP-4055 (closed circles), and with gemcitabine (closed triangles).
CP-4055 combinations in leukemia/lymphoma 791gemcitabine was most pronounced when the drugs
were given simultaneously or when CP-4055 was
administered ﬁrst (panel C). The interaction of CP-
4055 with cloretazine was additive except when CP-
4055 was dosed ﬁrst, which produced moderate
antagonism (panel A). Only the additive interaction
of CP-4055 with idarubicin was sequence-
independent (panel B). By comparison, drug inter-
actions in U937 cells were generally less sequence
dependent, with the exception of cloretazine
where synergy was observed when this agent was
administered prior to CP-4055 (Figure 4, panel A).
Notably, the signiﬁcant synergy seen with the
topoisomerase inhibitors when preceded by CP-
4055 in HL-60 cells was less pronounced in the
U937 model (panels D, E).
Drug ratio impacts anti proliferative response
In HL-60 cells, the CP-4055þgemcitabine simulta-
neous combination is highly synergistic across a wide
range of drug ratios as evidenced by the large
rectangle of blue contours (Figure 5, panel A). The
map for the cytarabineþgemcitabine combination is
similar; although the area of high synergy is reduced
(panel B). Areas of signiﬁcant synergy are also
observed with the other drug combinations, but the
majority of the maps are in the additive (green)
range. Notably, there are very few drug ratios in the
antagonistic range (orange-red) in HL-60 cells.
Results in HL-60 contrast with those seen in U937
cells (Figure 6). The synergistic region of the CP-
4055þgemcitabine map remains predominant, but a
small region of moderate antagonism is apparent.
Likewise, the cytarabineþgemcitabine map remains
additive to synergistic. In contrast, strong anta-
gonism was observed at certain drug ratios in
the combinations of CP-4055 with cloretazine
(CE¼712 max; panel C), irinotecan (CE¼715
max; panel D) and topotecan (CE¼716 max; panel
Figure 4. Combination index plots of Chou-Talalay and impact of drug sequence in U937 cells. Drug interaction was assessed by the
combination index method as described in Figure 3 in U937 cells for the drug combination partners listed in each panel.
Table III. Dose reduction index for CP-4055 combined with














1Combined in a molar ratio of 400:1 (CP-4055:Gemcitabine).
792 D. J. Adams et al.F). These values tend to occur in the upper right-
hand quadrant of the map where the CP-4055:clor-
etazine ratio is 50.05; CP-4055:irinotecan is 50.5,
and CP-4055:topotecan is 510. The interaction of
CP-4055 with idarubicin is predominantly additive
and ratio independent, which is particularly
Figure 5. Effect of ratio on drug interaction in HL-60 cells. 3-Dimensional drug interaction analysis was performed for binary combinations
of CP-4055 in HL-60 cells as described in Methods. The combination effect surface is presented as a color-coded contour map where green
represents additivity, red antagonism and blue synergy. For clarity, the color spectrum has been constrained to the range 76t oþ6. Values
beyond those extremes were observed, but not discriminated (i.e. the blue corresponding to CE¼6 actually represents CE 6).
CP-4055 combinations in leukemia/lymphoma 793important since this will be the ﬁrst combination
tested in the clinic. Of note, evaluation of the impact
of drug ratio as a function of drug sequence indicates
that the CP-4055-idarubicin interaction is both ratio
and sequence-independent in both cell lines (data
not shown).
Exposure time impacts individual response to CP-4055
and gemcitabine, but not the drug interaction
Traditionally in drug development, more emphasis is
placed on the impact of drug concentration on
antitumour activity than on the effect of exposure
Figure 6. Effect of ratio on drug interaction in U937 cells. 3-Dimensional analysis was performed as in Figure 5 for the same drug
combinations but in the U937 cell line.
794 D. J. Adams et al.time. However, both are important for activity of
agents alone and in combination [27]. Consequently,
concentration-time analysis was performed on the
synergistic combination of CP-4055þgemcitabine
in HL-60 cells [Figure 7(A)]. Similar results were
obtained for U937 cells (data not shown) and
revealed that the anti proliferative activity of both
CP-4055 and gemcitabine conforms reasonably well
to the pharmacodynamic model C
n6T¼k, where C
is the IC50 concentration, T is exposure time, n is the
concentration coefﬁcient and k is an exposure
constant (Table IV). The value for n indicates the
relative impact of concentration versus time to effect.
In the case of HL-60 cells, CP-4055 concentration
has more impact than time (n¼2), whereas in U937
cells the contribution is similar (n¼1). The two
factors contribute equally for gemcitabine in both cell
lines. Interestingly, drug interaction is not markedly
affected by exposure time as shown in Figure 7(B).
The combination index (at the IC50) drops some-
what from 1 to 9 h and then remains constant to a
maximum of 54 h.
Discussion
Traditionally, selection of cytotoxic drugs for com-
bination chemotherapy has been empirical based on
differing mechanisms of action, non-overlapping
toxicities, overcoming multi-drug resistance, and
increasing dose-density to exploit tumour growth
kinetics. Clinically, agents are combined at their
maximum tolerated dose and associated schedule as
determined in late stage clinical trials. Even the
newer combinations of cytotoxic drugs with targeted
therapeutics follow these general principles. Often
however, drug combinations are evaluated in the
clinic without prior pre-clinical studies to help guide
the clinical protocol. The current work therefore
assessed the impact of drug sequence of administra-
tion, drug ratio and drug concentration versus
exposure time on interactions between the lipophilic
cytarabine analog, CP-4055 and several important
drugs for the treatment of human leukemia and
lymphoma.
CP-4055 is a pro-drug that generates cytarabine
following serum or intracellular esterase cleavage of
the elaidic acid moiety. In vitro anti proliferative
activity of CP-4055 compared with cytarabine has
been reported previously in other human leukemia
models using different assays and exposure times
(Table V). Of note, results of these experiments are
expressed in terms of CP-4055 and not the cytar-
abine produced or the active metabolite, ara-CTP.
Relative activity of CP-4055 to cytarabine is highly
variable across cell lines and even within the same
cell line, with CP-4055 to cytarabine IC50 ratios
ranging from 0.04 to 9. Unlike these studies, the
current work assessed survival of viable cells using an
ATP metabolic endpoint, which our laboratory has
found to correlate well with the MTS mitochondrial
metabolic assay and with the propidium iodide assay
for total nucleic acids, but with greater sensitivity. By
ATP assay, CP-4055 was active against HL60
leukemia and U937 lymphoma cells with an IC50
Figure 7. Effect of exposure time on the interaction of CP-4055
plus gemcitabine. Panel A: IC50 versus exposure time in HL-60
cells Is shown for CP-4055 (diamonds) and gemcitablne (trian-
gles) as single agents. Panel B: HL-60 (circles) or U937 (squares)
cells were exposed simultaneously to CP-4055 in combination
with gemcitabine at a ﬁxed ratio of 1:0.0025 or 1:0.02,
respectively. The combination index at the IC50 level of effect
was then determined at each indicated time point. Bars: intra-assay
standard error; lines: ﬁt of data to the pharmacodynamic model
C
n6T¼k.
Table IV. Pharmacodynamic model parameters for the simulta-




2 n Log(k) R
2
CP-4055 1.78 9.11 0.86 1.09 4.47 0.84
Gemcitabine 1.23 1.59 0.99 1.06 2.89 0.87
*Based on log(T)¼n log(C)þlog(k), where C is the IC50
concentration, n is the concentration coefﬁcient, k is the exposure
constant and R
2 is the Pearson linear correlation coefﬁcient.
CP-4055 combinations in leukemia/lymphoma 795that is clinically achievable, since the Cmax for CP-
4055 in patients with solid tumours is 64 mM and in
hematological malignancies as high as 700 mM [13].
Cytarabine was 4-fold more potent than CP-4055 in
both cell lines, suggesting that esterase activation of
CP-4055 was less efﬁcient in these models. The 20-
fold difference in sensitivity in HL-60 versus U937 to
both drugs was notable. The relative resistance of
HL-60 cells was not due to lack of immunoreactive
deoxycytidine kinase in this cell line [28], however
other metabolic factors could be involved, including
50-nucleotidase, cytidine deaminase and DNA poly-
merase [2].
Gandhi and colleagues [29,30] were the ﬁrst to
describe biochemical modulation of cytarabine by
drugs like ﬂudarabine that inhibit ribonucleotide
reductase and thereby increase the rate of ara-CTP
accumulation in leukemia. Clinical activity of the
combination of cytarabine with ﬂudarabine has been
documented in AML and in refractory or relapsed
ALL with further enhancement of efﬁcacy by
addition of G-CSF to create the so called FLAG
regimen [4]. Drug synergy has been observed
subsequently for the combination of cytarabine with
gemcitabine in HL-60 cells [ratio 1:0.44; CI¼0.82
[6]], as well as in AML patient samples [CI¼0.5
[5]]. The current work found comparable synergistic
activity in HL-60 cells with the CP-4055-
gemcitabine combination (CI¼0.4). Moreover, this
interaction was largely independent of drug se-
quence, drug ratio, and exposure time, which is
advantageous for clinical translation. Since the CP-
4055-gemcitabine interaction could exploit the to-
poisomerase I mechanism of gemcitabine [24],
interaction with other topoisomerase I inhibitors
was investigated. Moderate to strong synergy was
observed with CP-4055 and the topoisomerase I
inhibitors irinotecan and topotecan, but only when
administered after CP-4055. Administration of these
camptothecin analogs prior to CP-4055 resulted in
additive to antagonistic interactions.
Drug ratio analysis demonstrated the importance
of this parameter in guiding clinical translation.
While the CP-4055-gemcitabine map indicated a
broad range of synergistic ratios, maps for combi-
nations of CP-4055 with the camptothecins and
cloretazine indicated that strong antagonistic inter-
actions could occur if drug ratio was not carefully
controlled. Regulation of ﬁxed drug ratios is
feasible in vitro, but problematic in vivo. Mayer
et al. [31] have recently conﬁrmed the need to
control ratios of antitumor drugs, including the
combination of cytarabine with the anthracycline
daunorubicin. More important, they have demon-
strated that in vivo control is now possible by
encapsulating the two agents at their synergistic
ratio in liposomal carriers. Pre-clinical evaluation of
drug interaction coupled with this technology could
greatly improve antitumor activity. In addition, this
approach could shift design of combination regi-
mens from the current model, which assumes that
maximum therapeutic activity requires maximum
dose intensity for all drugs in the combination, to
one in which the subtleties of drug interaction are
recognised. The CP-4055-gemcitabine combination
is a prime example, where optimal synergy occurs
at CP-4055 to gemcitabine molar ratios of 400 to
1. Therefore, even as targeted therapeutics take
center stage in anticancer drug development, there
remains much room for optimizing the use of
traditional cytotoxic drugs to improve treatment of
human cancer.









CCRF-CEM 40 70 1.75 Cell Count 3–4 Breistol (ref. 10)
HL-60(TB) 200 ND
4 SRB 119 NCI
K-562 15849 1140 0.07 SRB 119 NCI
RPMI-8226 316228 172330 0.54 SRB 119 NCI
SR 251 973 3.87 SRB 119 NCI
MOLT-4 50 2 0.04 SRB 119 NCI
MOLT-4 0.1 0.9 9 Cell Count 3–4 Breistol (ref. 10)
U937 167 710 4.25 ATP 14 Current study
HL-60 2989 13387 4.48 ATP 24 Current study
1Ratio of the IC50 for CP-4055 to that of cytarabine.
2Sulforhodamine B stain for total protein.
3National Cancer Institute 60 cell line screen (http:dtp.nci.nih.gov; cytarabine is NSC 63878).
4Not determined.
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